Triggered by concerns over an increased risk of cardiovascular side effects, Merck announced on 30 September the withdrawal of rofecoxib (Vioxx), its leading drug for the management of rheumatoid ...
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces further clinical evidence ...
Netherton Syndrome is a rare genetic skin disorder ... Today Quoin is sharing additional data on that subject at 4 weeks post-discontinuation of treatment with QRX003. As the table below ...